About: Developing therapeutic monoclonal antibodies at pandemic pace

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Developing therapeutic monoclonal antibodies at pandemic pace Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Developing therapeutic monoclonal antibodies at pandemic pace
Creator	Kelley, Brian
source	Medline; PMC
abstract	The time from discovery to proof-of-concept trials could be reduced to 5–6 months from a traditional timeline of 10–12 months.
has issue date	2020-04-21(xsd:dateTime)
bibo:doi	10.1038/s41587-020-0512-5
bibo:pmid	32317764
has license	no-cc
sha1sum (hex)	c7cba0d346b0ccf45108ca8d7ae39dcc249dc0f0
schema:url	https://doi.org/10.1038/s41587-020-0512-5
resource representing a document's title	Developing therapeutic monoclonal antibodies at pandemic pace
has PubMed Central identifier	PMC7173776
has PubMed identifier	32317764
schema:publication	Nat Biotechnol
resource representing a document's body	covid:c7cba0d346b0ccf45108ca8d7ae39dcc249dc0f0#body_text
is schema:about of	named entity 'toxicology' named entity 'IND' named entity 'influenza' named entity 'clinically tested' named entity 'mAb' named entity '15,000' named entity 'CHO' named entity 'mAb' named entity 'toxicology' named entity 'cGMP' named entity 'passive immunization' named entity 'IND' named entity 'titer' named entity 'titer' named entity 'drug product' named entity 'infectious diseases' named entity 'cGMP' named entity 'clinical experience' named entity 'route of administration' named entity 'patient safety' named entity 'contract manufacturing' named entity 'bioreactors' named entity 'recombinant antibody' named entity 'drug substance' named entity 'CHO' named entity 'phase 1' named entity 'drug product' named entity 'cell line' named entity 'Escherichia coli' named entity 'unit operation' named entity 'drug substance' named entity 'drug substance' named entity 'IgG1' named entity 'mAbs' named entity 'phase 1' named entity 'toxicology' named entity 'critical path' named entity 'phase 1' named entity 'drug product' named entity 'decision-making' named entity 'bioreactors' named entity 'critical path' named entity 'cell lines' named entity 'pandemic outbreaks' named entity 'transfection' named entity 'cell culture media' named entity 'cGMP' named entity 'BLA' named entity 'High-throughput screening' named entity 'cell line' named entity 'clonally' named entity 'intravenous immunoglobulin' named entity 'IND' named entity 'IgG1' named entity 'clinical testing' named entity 'transfection' named entity 'H1N1' named entity 'cGMP' named entity 'IND' named entity 'clinical development' named entity 'drug product' named entity 'IND' named entity 'patient safety' named entity 'mAb' named entity 'clinical trial' named entity 'product manufacturing' named entity 'inoculum' named entity 'drug product' named entity 'clinical development' named entity 'pandemic disease' named entity 'cell line' named entity 'line buffer' named entity 'cGMP' named entity 'cell lines' named entity 'mAb' named entity 'Fig. 1' named entity 'cloning' named entity 'phase 1 clinical trials' named entity 'drug substance' named entity 'IND' named entity 'cloning'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software